Results 11 to 20 of about 2,808,349 (298)
Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis. [PDF]
PLoS ONE, 2013 BACKGROUND: Optimal regimen choice of antiretroviral therapy is essential to achieve long-term clinical success. Integrase inhibitors have swiftly been adopted as part of current antiretroviral regimens.
Peter Messiaen +5 more
doaj +11 more sources
HIV-1 integrase polymorphisms are associated with prior antiretroviral drug exposure [PDF]
Retrovirology, 2009 In a recent summary of integrase sequences, primary integrase inhibitor mutations were rare. In a review of integrase inhibitor-naïve Australian HIV-1 sequences, primary mutations were not identified, although the accessory mutation G140S was detected. A
Wang Bin +5 more
doaj +5 more sources
Biomath, 2012 Antiviral combination therapies consisting of reverse transcriptase inhibitors, protease inhibitors and an integrase inhibitor, have been developed to suppress HIV below the limit of detection.
Dimitra Bon +3 more
doaj +3 more sources
HIV/HCV-coinfection: which role can new antiretrovirals such as integrase inhibitors play? [PDF]
European Journal of Medical Research, 2009 End-stage liver disease has become one of the most frequent causes of death in HIV/HCV-coinfected patients. The role of new antiretrovirals in the progression of liver fibrosis has yet to be defined.
Vogel Martin, Nelson Mark
doaj +2 more sources
Patterns of resistance development with integrase inhibitors in HIV
Infection and Drug Resistance, 2011 Raltegravir, the only integrase (IN) inhibitor approved for use in HIV therapy, has recently been licensed. Raltegravir inhibits HIV-1 replication by blocking the IN strand transfer reaction. More than 30 mutations have been associated with resistance to raltegravir and other IN strand transfer inhibitors (INSTIs).
P Cane, Jean L. Mbisa, Martín
openalex +5 more sources
Weight change with antiretroviral switch from integrase inhibitor or tenofovir alafenamide-based to Doravirine-Based regimens in people with HIV [PDF]
HIV Research & Clinical PracticeBackground Weight gain has been well-described with integrase strand transfer inhibitors (INSTIs) and tenofovir alafenamide (TAF). Doravirine (DOR) has been identified as a relatively “weight-neutral” drug; however, there is little data describing its ...
Arianna E. Kousari +6 more
doaj +2 more sources
Raltegravir: first in class HIV integrase inhibitor
Therapeutics and Clinical Risk Management, 2008 Zelalem Temesgen1, Dawd S Siraj21Mayo Clinic, Rochester, MN, USA; 2East Carolina University Greenville, NC, USAAbstract: On October 16, 2007, the US Food and Drug Administration (FDA) approved raltegravir for treatment of human immunodeficiency virus ...
Zelalem Temesgen, Dawd S Siraj
doaj +5 more sources
Weight gain and integrase inhibitors [PDF]
Current Opinion in Infectious Diseases, 2020 Purpose of review Weight gain and obesity among people living with HIV (PLWH) is a serious problem that occurs often after initiation of antiretroviral therapy but may be worse with integrase strand transfer inhibitors (INSTIs).
Grace A. McComsey, Allison Ross Eckard
openaire +3 more sources
Open Forum Infectious Diseases, 2021 Background Emerging data demonstrate that the use of integrase inhibitor (INSTI)-based antiretroviral treatment (ART) is associated with increased weight, but the cardiometabolic health consequences of increased weight remains poorly understood.
E. M. Kileel +15 more
semanticscholar +1 more source
PLoS Pathogens, 2021 Allosteric integrase inhibitors (ALLINIs) are a class of experimental anti-HIV agents that target the noncatalytic sites of the viral integrase (IN) and interfere with the IN-viral RNA interaction during viral maturation.
T. Maehigashi +10 more
semanticscholar +1 more source